Showing 2 of 10 years of data. Sign up free for 5 years of history.
View Plans2-year trend showing gross, operating, and net profit margins
Glaxosmithkline Pharmaceuticals Ltd.'s net profit margin of 27.1% in FY2026 reflects excellent profitability, with operating margin at 32.5% and gross margin at 64.6%.
In FY 2026, Glaxosmithkline Pharmaceuticals Ltd. posted a gross margin of 64.6%, an operating margin of 32.5%, a net margin of 27.1%. Gross Margin = (Revenue - COGS) / Revenue; Operating Margin = EBIT / Revenue; Net Margin = Net Income / Revenue. Typical healthy ranges: Gross 20-40%, Operating 10-20%, Net 5-10%+. Consistent or improving margins indicate strong competitive positioning.
2-year trend showing revenue, gross profit, and net profit
Glaxosmithkline Pharmaceuticals Ltd.'s revenue declined 1.9% to 38.22B in FY2026, though net profit grew 11.7% to 10.36B.
In FY 2026, Glaxosmithkline Pharmaceuticals Ltd.'s revenue declined by 1.9% year-over-year. Revenue is total income from operations. Gross Profit is revenue minus cost of goods. Net Profit is the bottom line after all expenses. Consistent growth across all three signals a healthy, expanding business.
2-year trend showing shareholder returns
Glaxosmithkline Pharmaceuticals Ltd.'s ROE of 45.7% in FY2026 indicates excellent capital efficiency.
In FY 2026, Glaxosmithkline Pharmaceuticals Ltd. reported an ROE of 45.7%. ROE = (Net Income / Shareholders' Equity) x 100. Measures how efficiently the company turns equity into profit. Above 15% is generally strong; above 25% is excellent. Very high ROE may signal high leverage — check alongside debt levels.
2-year trend comparing profitability with cash generation
Glaxosmithkline Pharmaceuticals Ltd.'s FCF/NI ratio of 0.82x in FY2026 indicates reasonable cash generation relative to profits.
In FY 2026, Glaxosmithkline Pharmaceuticals Ltd.'s free cash flow trailed net income. Free Cash Flow = Operating Cash Flow - Capital Expenditure. When FCF exceeds net income, it suggests high-quality, cash-backed earnings. Persistent gaps may indicate aggressive accounting or heavy capex needs.
2-year trend comparing profitability with cash from operations
Glaxosmithkline Pharmaceuticals Ltd.'s OCF/NI ratio of 0.87x in FY2026 indicates reasonable cash conversion from operations.
In FY 2026, Glaxosmithkline Pharmaceuticals Ltd.'s operating cash flow trailed net income. Operating Cash Flow is the actual cash from core operations. OCF exceeding net income signals strong cash collection. OCF trailing net income may indicate aggressive revenue recognition or working capital issues.
Measure a company's financial leverage, liquidity, and ability to meet financial obligations.
2-year trend showing short-term liquidity position
Glaxosmithkline Pharmaceuticals Ltd.'s current ratio of 2.03x in FY2026 indicates healthy short-term liquidity.
In FY 2026, Glaxosmithkline Pharmaceuticals Ltd. reported a current ratio of 2.03. Current Ratio = Current Assets / Current Liabilities. Measures short-term liquidity. A ratio of 1.5-3.0 is generally healthy; below 1.0 signals liquidity risk; above 3.0 may indicate underutilized assets.
2-year trend showing ability to service debt
Glaxosmithkline Pharmaceuticals Ltd.'s interest coverage ratio of 454.8x in FY2026 indicates comfortable debt servicing capacity.
In FY 2026, Glaxosmithkline Pharmaceuticals Ltd. reported an interest coverage ratio of 454.8x. Interest Coverage = EBIT / Interest Expense. Shows how many times operating profit covers interest payments. Above 5x is comfortable; below 1.5x signals potential difficulty servicing debt.
2-year trend showing financial leverage and capital structure
Glaxosmithkline Pharmaceuticals Ltd.'s debt-to-equity ratio of 0.01x in FY2026 reflects a conservative, low-leverage capital structure.
In FY 2026, Glaxosmithkline Pharmaceuticals Ltd. reported a debt-to-equity ratio of 0.01. Debt-to-Equity = Total Debt / Total Equity. Below 1.0 is conservative; 1.0-2.0 is moderate; above 2.0 indicates higher financial risk. Capital-intensive industries naturally carry higher ratios.
2-year trend showing total debt with year-over-year changes
Glaxosmithkline Pharmaceuticals Ltd.'s debt increased 234.4% YoY in FY2026 — rising leverage demands close monitoring.
In FY 2026, Glaxosmithkline Pharmaceuticals Ltd.'s total debt increased by 234.4% year-over-year. Total Debt includes short-term debt, long-term loans, debentures, and capital leases. YoY changes (shown as percentages) reveal whether the company is leveraging up or deleveraging.
Year-over-year change in diluted shares outstanding
Glaxosmithkline Pharmaceuticals Ltd.'s diluted shares remained virtually unchanged in FY2026.
Over 2 years (FY2025–FY2026), diluted shares remained essentially unchanged at 169.41M.
In FY 2026, Glaxosmithkline Pharmaceuticals Ltd.'s diluted shares increased by 0.0% year-over-year. Diluted Shares accounts for stock options, warrants, and convertibles. Positive YoY change means dilution (red); negative means buybacks (green). Consistent dilution above 5% annually is a red flag.
You're viewing 2 years of data. Upgrade to access 10 years of financial ratios, margins, and performance metrics.
Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: FY 2026